Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China
NCT ID: NCT06655090
Last Updated: 2024-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2021-12-01
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Disease-syndrome Characteristics of IPF
NCT07178392
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis
NCT05895409
Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
NCT06629623
Idiopathic Pulmonary Fibrosis Registry China Study
NCT03666234
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients refused to participant
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The First Affiliated Hospital of Guangzhou Medical University
OTHER
Nankai University
OTHER
Jilin University
OTHER
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Shanghai Chest Hospital
OTHER
Institute of Basic Medical Sciences CAMS
UNKNOWN
Tongji Hospital
OTHER
National Institute for Occupational Health and Poison Control
UNKNOWN
Infervision Medical Technology Company Limited
UNKNOWN
Dai Huaping
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dai Huaping
Department of Pulmonary and Critical Care Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huaping Dai, M.D. Ph.D.
Role: STUDY_DIRECTOR
China-Japan Friendship Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ChinaJapanFH006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.